Objective: To investigate the incidence of cisplatin-induced nephrotoxicity through hyperthermic intraperitoneal chemotherapy (HIPEC) for gastrointestinal tumors. Methods: From January 2012 to July 2013, a consecutive series of 99 patients undergoing HIPEC were retrospectively reviewed. The patients were divided into cisplatin group and non-cisplatin group, and received HIPEC combined with cisplatin or not. Renal function parameters, nutritional status and immune function were compared between the two groups. Results: Based on the RIFLE classification, four patients developed acute kidney injury and six slight renal insufficiency in the cisplatin group, and no patients had renal failure. The incidence of cisplatin-induced nephrotoxicity was 21.3%. The BUN and creatinine levels significantly increased after perfusion therapy in the cisplatin group, were significantly higher than those in the non-cisplatin group. However, there were no significant differences in postoperative pain scaled with VAS score, albumin level and hospital stay between the two groups. Conclusion: Cisplatin-based HIPEC could increase the risk of postoperative nephrotoxicity. Renal function should be strictly monitored during cisplatinbased chemotherapy.